The BCR-ABL1 fusion drives two hematopoietic malignancies—chronic myelogenous leukemia (CML), a myeloproliferative disorder, and BCR-ABL1 lymphoblastic leukemia, an acute leukemia mostly of the B-cell lineage. This evidence concerns the gene BCR and acute lymphoblastic leukemia.